Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DNA damage, p53 and anticancer therapies

Nature Medicine volume 1, pages 879–880 (1995)Cite this article

As knowledge about the importance of the p53 protein grows, so do the number of potential options for successful treatment of cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lee, S., Elenbaas, B., Levine, A. & Griffith, J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81, 1013–1020 (1995).

    Article  CAS  Google Scholar 

  2. Jayaraman, L. & Prives, C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81, 1021–1029 (1995).

    Article  CAS  Google Scholar 

  3. Molinari, M. & Milner, J. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6. Oncogene 10, 1849–1854 (1995).

    CAS  PubMed  Google Scholar 

  4. Cho, Y., Gorina, S., Jeffrey, P.D. & Pavletich, N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumourigenic mutations. Science 265, 346–355 (1994).

    Article  CAS  Google Scholar 

  5. Rolley, N., Butcher, S. & Milner, J. Specific DNA binding by different classes of human p53 mutants. Oncogene (in the press).

  6. Crawford, L.V., Pim, D. & Lamb, P. The cellular protein p53 in human tumours. Molec. biol. Med. 2, 261–272 (1984).

    CAS  PubMed  Google Scholar 

  7. Medcalf, E.A. & Milner, J. Targeting and degradation of p53 by E6 of human papilloma virus type 16 is preferential for the 1620+ p53 conformation. Oncogene 8, 2847–2851.

  8. Wang, Y. & Prives, C. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376, 88–l91 (1995).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology, University of York, York, Y01 5DD, UK

    Jo Milner

Authors
  1. Jo Milner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milner, J. DNA damage, p53 and anticancer therapies. Nat Med 1, 879–880 (1995). https://doi.org/10.1038/nm0995-879

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0995-879

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing